169 results on '"K. Ridwelski"'
Search Results
2. Risk profile analysis and complications after surgery for autoimmune thyroid disease
- Author
-
O Thomusch, C Sekulla, F Billmann, G Seifert, H Dralle, K Lorenz, C Vorländer, M Freitag, J Jähne, T Steinmüller, A Trupka, F Steinert, J Schabram, B Heinzmann, H Lang, J Cotte, T F Hoffmann, K Dette, K Gellert, D Henne-Bruns, J Boese-Landgraf, D Simon Evangelisches, R Kube, E P M Lorenz, M Pross, M Hartel, D Thomschke, G Pistorius, U T Hopt, C Franke, U Rose, W Steuer, W Schwenk, K-H Ebert, C Kelm, H Witzigmann, W Rampf, K Ridwelski, W T Knoefel, W O Bechstein, D Grothe, M Anthuber, L Mirow, W Probst, A Thews, U Fleck, W Kärgel, H Schimmelpenning, J Fielitz, T Schöffauer, W Asperger, J Zaage, H-U Dorn, J Weitz, M Neubauer, E Klar, J Lautermann, M Senkal, H Lippert, R Lück, M Ziesche, K-P Kröll, J Skrobisz, Z Lorenc, B Dudesek, S Smutny, M Brauckhoff, F Längle, and E Wenzl more...
- Subjects
Adult ,Male ,medicine.medical_specialty ,Goiter ,medicine.medical_treatment ,030209 endocrinology & metabolism ,Hashimoto Disease ,Thyroiditis ,03 medical and health sciences ,Postoperative Complications ,0302 clinical medicine ,Risk Factors ,medicine ,Humans ,Prospective Studies ,Vocal cord paralysis ,Risk factor ,Thyroiditis, Subacute ,business.industry ,Thyroid ,Age Factors ,Thyroidectomy ,Middle Aged ,medicine.disease ,Multinodular goitre ,Graves Disease ,Surgery ,Logistic Models ,medicine.anatomical_structure ,Hypoparathyroidism ,030220 oncology & carcinogenesis ,Female ,business ,Goiter, Nodular - Abstract
Background Surgical approaches to autoimmune thyroid disease are currently hampered by concerns over postoperative complications. Risk profiles and incidences of postoperative complications have not been investigated systematically, and studies with sufficient power to show valid data have not been performed. Methods A prospective multicentre European study was conducted between July 2010 and December 2012. Questionnaires were used to collect data prospectively on patients who had surgery for autoimmune thyroid disease and the findings were compared with those of patients undergoing surgery for multinodular goitre. Logistic regression analysis was used to evaluate risk factors for thyroid surgery-specific complications, transient and permanent recurrent laryngeal nerve (RLN) palsy and hypoparathyroidism. Results Data were available for 22 011 patients, of whom 18 955 were eligible for analysis (2488 who had surgery for autoimmune thyroid disease and 16 467 for multinodular goitre). Surgery for multinodular goitre and that for autoimmune thyroid disease did not differ significantly with regard to general complications. With regard to thyroid surgery-specific complications, the rate of temporary and permanent vocal cord palsy ranged from 2·7 to 6·7 per cent (P = 0·623) and from 0·0 to 1·4 per cent (P = 0·600) respectively, whereas the range for temporary and permanent hypoparathyroidism was 12·9 to 20·0 per cent (P < 0·001) and 0·0 to 7·0 per cent (P < 0·001) respectively. In logistic regression analysis of transient and permanent vocal cord palsy, autoimmune thyroid disease was not an independent risk factor. Autoimmune thyroid disease, extent of thyroid resection, number of identified parathyroid glands and no autotransplantation were identified as independent risk factors for both transient and permanent hypoparathyroidism. Conclusion Surgery for autoimmune thyroid disease is safe in comparison with surgery for multinodular goitre in terms of general complications and RLN palsy. To avoid the increased risk of postoperative hypoparathyroidism, special attention needs to be paid to the parathyroid glands. more...
- Published
- 2018
- Full Text
- View/download PDF
Catalog
3. Roboterassistierte Rektumkarzinomchirurgie
- Author
-
B. M. Ghadimi, Marian Grade, B Mann, K Ridwelski, and I Voigt
- Subjects
Laparoscopic surgery ,medicine.medical_specialty ,Colorectal cancer ,business.industry ,medicine.medical_treatment ,Retrospective cohort study ,Perioperative ,medicine.disease ,Total mesorectal excision ,Da Vinci Surgical System ,3. Good health ,Surgery ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,medicine ,030211 gastroenterology & hepatology ,business ,Mesorectal ,Cohort study - Abstract
Background The oncological outcome of patients with rectal cancer has improved considerably over the past few decades. This is mainly due to the introduction of the surgical concept of total mesorectal excision (TME) and the implementation of multimodal treatment strategies. Additionally, it has recently been demonstrated that the oncological results of open and laparoscopic TME are comparable. For some time there has been an ongoing debate on the potential relevance of robotic assistance systems in visceral surgery. The aim of this study was to evaluate the operative and perioperative outcomes of patients with rectal or rectosigmoid cancer, who were operated on using the Da Vinci Surgical System. Patients and results We retrospectively analysed the outcomes of 202 consecutive patients, who were operated between September 2010 and November 2015 in three Surgical Centers. The cohort consisted of 136 men and 66 women with a mean BMI of 28. We performed the following procedures: 49 anterior rectal resections, 119 low anterior rectal resections, and 34 abdominoperineal excisions. Conversion to an open procedure was required in 13 patients. Non-surgical complications (n = 27) occurred in 24 patients (12%) and surgical complications (n = 67) in 62 patients (31%). Most complications were due to abdominal or sacral wound infections (n = 25) and anastomotic leaks (n = 18). The mortality rate within 30 days was 2%. The rate of R0 resections was 95%, with circumferential resection margins being negative in 98% of the patients. The quality of the mesorectal resection was scored as good in 91% of the patients. Conclusions The Da Vinci Surgical System can be used safely and with a low complication rate for surgical treatment of rectal cancer. While primary evidence suggests that the outcome of robotic-assisted surgery is comparable with open and laparoscopic surgery, its definitive value has to be determined upon publication of the prospective randomized ROLARR trial. The main advantages of the Da Vinci system are its endowristed instruments with multiple degrees of freedom and its optimised visualisation (3D, stable camera platform controlled by the surgeon). Another positive feature is the significant ergonomic advantage for the surgeon. more...
- Published
- 2016
- Full Text
- View/download PDF
4. Ernährung beim Magenkarzinom
- Author
-
F Raddatz, K Ridwelski, C Meißner, S Maluck-Schölecke, and K Rendel
- Published
- 2018
- Full Text
- View/download PDF
5. Vollständigkeit und Qualität der Basisdaten und der Nachbeobachtung im Krebsregister
- Author
-
K. Ridwelski, Siegfried Kropf, Hans Lippert, I. Radinski, A. Altendorf-Hofmann, E. Burger, and Johannes Bernarding
- Subjects
Gynecology ,medicine.medical_specialty ,Political science ,medicine ,General Medicine - Abstract
Hintergrund und Fragestellung | In der Bundesrepublik Deutschland werden Tumorerkrankungen nicht nur in epidemiologischen, sondern auch in klinischen Registern erfasst, welche die Vernetzung der Behandlung, die Qualitatskontrolle und die klinische Forschung unterstutzen. Voraussetzung dazu ist die in dieser Arbeit untersuchte Vollstandigkeit der Erfassung. Patienten und Methode | Wir verglichen die Daten aus dem klinischen Krebsregister Magdeburg und dem Register des An-Instituts fur Qualitatssicherung in der operativen Medizin gGmbH an der Otto-von-Guericke-Universitat Magdeburg. Anhand der erfassten Daten von Patienten mit kolorektalem Karzinom aus zwei grosen Magdeburger Kliniken bewerteten wir den Erfassungsgrad bzw. die Vollstandigkeit der Daten und suchten nach systematischen Einflussfaktoren auf diese Kennziffern. Ergebnisse | Von den im An-Institut erfassten Patienten waren 78,9 % im klinischen Krebsregister aufgefuhrt. Die Erfassungsrate verbesserte sich uber die Zeit, hing aber auch von diagnostischen Kenngrosen wie dem Krebsstadium ab. Man erkennt Unterschiede zwischen beiden Registern, die auf ihre spezifischen Zielstellungen zuruckgehen. Besonders in der Nachbeobachtung zeigten sich Gefahren fur verfalschte Schatzungen aus den Registerdaten. Folgerung | Die Sicherung von Vollzahligkeit, Vollstandigkeit, Korrektheit und Aktualitat der Erfassung der Daten ist eine wichtige Forderung an die Krebsregister, da Schatzungen von Qualitatsparametern wie Uberlebenszeiten deutlich davon abhangen. more...
- Published
- 2015
- Full Text
- View/download PDF
6. [R1 resection for gastric carcinoma]
- Author
-
K, Ridwelski, J, Fahlke, M, Huß, R, Otto, and S, Wolff
- Subjects
Male ,Reoperation ,Margins of Excision ,Adenocarcinoma ,Prognosis ,Combined Modality Therapy ,Neoadjuvant Therapy ,Survival Rate ,Gastrectomy ,Risk Factors ,Stomach Neoplasms ,Lymphatic Metastasis ,Frozen Sections ,Humans ,Lymph Node Excision ,Female ,Esophagogastric Junction ,Guideline Adherence ,Neoplasm Staging - Abstract
The results reported in the literature in the context of an R1 situation for a resected gastric carcinoma are not uniform. An R1 situation worsens the prognosis for the long-term survival of patients. This is significant especially for low T stages and lymph node metastasis with 0-≤3 lymph node metastases. In higher tumor stages with extensive lymph node metastases, the survival difference between R0 and R1 resections is lower and frequently no longer significant. The frequency of R1 resection is approximately 5% (range 1.8-9%) and for adenocarcinoma of the esophagogastric junction (AEG tumors)10%. The data are mainly related to the oral and aboral resection line but there are only a few specifications on the circumferential margin. The risk of an infiltrated resection line increases with the size of the tumor (5 cm), T3+4 and pN2/pN3 stages. Poorly differentiated signet ring cell or mucinous adenocarcinomas and carcinomas of the Bormann type 3+4 also lead to an increased R1 rate. In order to achieve an R0 resection, an intraoperative frozen section is the standard approach. Immediate reoperation should be performed in the case of tumor infiltration. If an R1 resection is detected only in the definitive histology, surgical re-excision to achieve an R0 resection is the standard approach in publications. Nevertheless, a reoperation is rare. Only 1 study showed 122 patients with 100% re-operations, which were successfully performed in 50 patients (41% R0). For the R0 group, median survival was extended from 18 months to 23 months. There are only sporadic literature data and no evidence for postoperative additive treatment (chemotherapy, radiotherapy and radiochemotherapy). more...
- Published
- 2017
7. Roboter-assistierte Chirurgie des Rektumkarzinoms: Erfahrungen dreier Zentren
- Author
-
M Ghadimi, Marian Grade, M Benno, I Voigt, and K Ridwelski
- Subjects
Gastroenterology - Published
- 2016
- Full Text
- View/download PDF
8. S3-Leitlinie 'Magenkarzinom'
- Author
-
H. Vogelsang, Stefan Mönig, C. Kuhn, Lars Grenacher, Wolfgang Fischbach, Andrea Tannapfel, Markus Moehler, Wh-H. Schmiegel, J. Bernhardt, Michael Stahl, T. Rabenstein, C. Stoll, Hubert J. Stein, Stephan Kanzler, A. Weimann, Manfred P. Lutz, J. Körber, Michael Flentje, P. Rohr, R. Porschen, U. Vanhoefer, Markus Horneber, I. Roetzer, Hj-J. Meyer, J. Fahlke, Bj J. Krause, T. Andus, Pm M. Schlag, Frank Kullmann, P. Baier, K. Ridwelski, W. Schepp, B. Herbst, Helmut Messmann, U. Wedding, Wa A. Diemer, Pr R. Galle, E. Burmester, Ah H. Hölscher, He E. Gabbert, C. Ell, Florian Lordick, S. Groß, H. Boeing, G. Klautke, J. Seraphin, E. Böhle, Cf F. Dietrich, Rd D. Hofheinz, MP Ebert, Dirk Arnold, A. Eickhoff, Christian Jenssen, W. Budach, K. Ludwig, T. Seufferlein, K. Treml, A. Sendler, M. Heike, H. Wilke, R. Tholen, Rainer Fietkau, T. Höhler, H. Feußner, M Vieth, W. Fleig, Michael Selgrad, S. Merkel, Ch. Wittekind, Peter C. Thuss-Patience, Heinz Höfler, Gustavo B. Baretton, Peter Malfertheiner, M. Keller, Carsten Bokemeyer, Ralf Kiesslich, Ines Gockel, Jan Bornschein, Christoph Röcken, Steffen Pistorius, M. Geissler, Kerstin Schütte, G. Schuch, D. Wagner, Christoph Schuhmacher, R. Jakobs, U. Graeven, H. Lang, P. Piso, W. Schwenk, Hj-J. Schmoll, M. Anthuber, Jt T. Hartmann, J. Hübner, S. Höcht, J. R. Izbicki, Volker Heinemann, Daniela Aust, R. Mahlberg, Hartmut Link, Heinz Schmidberger, RM Schmid, P. Reichardt, Se-E. Al-Batran, Martin Stuschke, Thomas Herrmann, K. Caca, and Jann Arends more...
- Subjects
German ,medicine.medical_specialty ,Esophagogastric cancer ,business.industry ,General surgery ,Gastroenterology ,MEDLINE ,language ,Medicine ,Guideline ,business ,language.human_language - Published
- 2011
- Full Text
- View/download PDF
9. Oxaliplatin for Chemotherapeutic Treatment and Prevention of Experimental Peritoneal Carcinomatosis in Rats Comparing the Intraperitoneal and Intravenous Application Mode
- Author
-
Hans Lippert, K. Ridwelski, A. Hribaschek, Frank Meyer, and Doerthe Kuester
- Subjects
Oncology ,medicine.medical_specialty ,Organoplatinum Compounds ,Colorectal cancer ,medicine.medical_treatment ,Antineoplastic Agents ,Adenocarcinoma ,Resection ,Cell Line, Tumor ,Internal medicine ,medicine ,Animals ,Peritoneal Neoplasms ,Chemotherapy ,business.industry ,Carcinoma ,Organ Size ,medicine.disease ,Combined Modality Therapy ,digestive system diseases ,Rats ,Peritoneal carcinomatosis ,Oxaliplatin ,Disease Models, Animal ,Injections, Intravenous ,Surgery ,business ,Cell Division ,medicine.drug - Abstract
Background: The occurrence of peritoneal carcinomatosis after resection of colorectal carcinoma is still a major concern. In this study, we tested the cytostatic agent oxaliplatin delivered intraperitoneally and intravenously to prove whether it can significantly reduce intraperitoneal tumor growth. Methods: Peritoneal tumor growth was experimentally induced with transfer of CC-531 colon cancer cells (5 × 106) to the peritoneal surface of rats via laparotomy. Oxaliplatin was delivered either intraperitoneally or intravenously. In group A, oxaliplatin was administered directly after tumor cell transfer. While oxaliplatin was applied in group B on days 5, 10, and 15 after tumor cell implantation, in group C, it was administered on days 10, 15 and 20. The rats were sacrificed on day 30 after tumor cell transfer. Tumor weight, relative increase in tumor mass, volume of malignant ascites and the number of tumor nodes were determined. Results: Oxaliplatin significantly inhibited tumor growth after direct (group A) and early postoperative application (group B) via the intraperitoneal route. The late postoperative administration of oxaliplatin (group C) did not cause a significant effect on peritoneal tumor growth as it did with the intravenous application mode in groups A, B, and C. Conclusions: In this experimental model, oxaliplatin was highly effective against intraperitoneal tumor spread but only with the intraperitoneal application route. Other cytostatic agents with different effector mechanisms should be combined with oxaliplatin to further increase the therapeutic efficacy of the favorable intraperitoneal treatment in subsequent studies testing, in addition, the effects on wound and anastomosis healing. more...
- Published
- 2009
- Full Text
- View/download PDF
10. Contents Vol. 53, 2007
- Author
-
Pan Wang, Yuichi Tanaka, Sebastian G. B. Amyes, J. Fahlke, George Dimitracopoulos, Quanhong Liu, Frank Meyer, Hidetsugu Nakayama, Chieko Murayama, Maja A. Hofmann, Iris Spiliopoulou, Yoichi Tanaka, Matthias Pross, G. Royo, Uwe Trefzer, K. Ridwelski, Hiroya Takami, H. Lippert, Myrto Christofidou, Regine Schneider-Stock, Seiei Yasuda, Arndt Hribaschek, Lina Xiao, Karsten Ridwelski, Yoshikazu Gotoh, Sofia Zografou, Kenji Ishikawa, Hiroko Sasahara, Wolfram Sterry, Hussien O. AlKadi, I. Escribano, Akemi Kamijo, Susumu Sueyoshi, Toshiaki Tanaka, Verena Gabriel, B. Llorca, J.C. Rodríguez, F. Garcia e Costa, Naoki Mori, T. Deist, T. Nagano, Fiona Walsh, Sotaro Sadahiro, Xiaobing Wang, Phil Turner, Kazuo Shirouzu, Annett Milling, Hiromasa Fujita, U. Keilholz, M. Assmann, Hans Lippert, D. Quietzsch, Yuji Maeda, P. Stuebs, E. García-Pachon, Rajesh Pandey, Gopal K. Khuller, Shinichiro Akiyama, Zerrin Yulugkural, M.L. Pereira, Toshiyuki Suzuki, Simon Bracher, Felix Kiecker, K. Hribaschek, Haluk Vahaboglu, Sıla Akhan, C. Schmidt, M. Ruiz, Hiromichi Gotoh, Amalia Goula, Hideaki Yamana, E. Kettner, and Hiroyasu Makuuchi more...
- Subjects
Pharmacology ,Infectious Diseases ,Oncology ,Drug Discovery ,Pharmacology (medical) ,General Medicine - Published
- 2007
- Full Text
- View/download PDF
11. [Completeness and quality of baseline data and follow-up in cancer registry--an analysis on the example of colorectal cancer]
- Author
-
S, Kropf, E, Burger, I, Radinski, K, Ridwelski, H, Lippert, A, Altendorf-Hofmann, and J, Bernarding
- Subjects
Adult ,Aged, 80 and over ,Male ,Skin Neoplasms ,Lymphoma ,Gastrointestinal Stromal Tumors ,Sarcoma ,Middle Aged ,Survival Rate ,Neuroendocrine Tumors ,Bias ,Research Design ,Germany ,Perceptual Closure ,Humans ,Female ,Registries ,Colorectal Neoplasms ,Melanoma ,Carcinoma in Situ ,Aged ,Follow-Up Studies - Abstract
In Germany, data of cancer patients are recorded not only in epidemiological registers but also in clinical cancer registers. To ensure the networking of all included medical partners, quality control, and clinical research it is necessary that cancer cases are captured more or less completely. The aim of the present study was to compare the data sets of two registers.Data from patients with colorectal cancer from two large surgical clinics in Magdeburg are recorded in two registers - the Clinical Cancer Registry Magdeburg and the Institute of Quality Assurance in Operative Medicine at the Otto-von-Guericke University Magdeburg. Here we compared the data sets in order to check the completeness of data capturing and to determine factors influencing the degree of completeness.From all patients captured in the Institute of Quality Assurance, 78.9% are found also in the clinical cancer registry. The percentage improves over the course of time, but also depends on diagnostic criteria such as the staging. There are some differences between both registries, explainable by their specific objectives. Particularly, it is demonstrated that incomplete follow-up record may bias estimates of survival rates from registries.Ensuring the completeness and correctness of data is a major challenge for cancer registries. It has distinct influence on estimated quality parameters such as survival rates. more...
- Published
- 2015
12. Retroperitoneal schwannoma presenting as an adrenal tumor
- Author
-
Hans Lippert, Hendrik Lehnert, Daniel Pittasch, K Ridwelski, Silke Klose, Johannes Schmitt, and Albert Roessner
- Subjects
Abdominal pain ,Pathology ,medicine.medical_specialty ,Endocrinology, Diabetes and Metabolism ,medicine.medical_treatment ,Adrenal Gland Neoplasm ,Adrenal Gland Neoplasms ,Schwannoma ,Diagnosis, Differential ,Endocrinology ,Internal Medicine ,medicine ,Humans ,Endocrine system ,Retroperitoneal Neoplasms ,Ultrasonography ,Adrenal gland ,business.industry ,Adrenalectomy ,General Medicine ,Middle Aged ,medicine.disease ,Magnetic Resonance Imaging ,Retroperitoneal Neoplasm ,medicine.anatomical_structure ,Female ,medicine.symptom ,Differential diagnosis ,Tomography, X-Ray Computed ,business ,Neurilemmoma - Abstract
A retroperitoneal tumor in the region of the adrenal gland was diagnosed in a 56-year-old woman. The patient had been suffering from a dull abdominal pain for nearly four weeks before consulting her family physician. Ultrasound, CT and MRI scans revealed a giant tumor of the right adrenal gland. Endocrine activity could not be demonstrated. The size of the tumor was suggestive of an adrenal carcinoma. The patient was referred for adrenalectomy and complete exstirpation of the retroperitoneal mass. The histological examination revealed characteristical findings of a benign schwannoma. more...
- Published
- 2000
- Full Text
- View/download PDF
13. [Surgical treatment of carcinomas of the oesophagogastric junction - results achieved in multicentre studies]
- Author
-
R, Steinert, I, Gastinger, K, Ridwelski, H, Ptok, S, Wolff, F, Meyer, R, Otto, and H, Lippert
- Subjects
Adult ,Aged, 80 and over ,Male ,Adenocarcinoma ,Middle Aged ,Combined Modality Therapy ,Neoadjuvant Therapy ,Survival Rate ,Young Adult ,Postoperative Complications ,Stomach Neoplasms ,Frozen Sections ,Humans ,Lymph Node Excision ,Female ,Esophagogastric Junction ,Hospital Mortality ,Prospective Studies ,Aged ,Neoplasm Staging - Abstract
Adenocarcinomas of the oesophagogastric junction are increasingly being considered as a separated tumour entity. The prognosis is rather poorer compared with that for distal gastric cancer. Data from a multicentre study as part of research on clinical care aim to reflect the current situation in surgical treatment after inauguration of neoadjuvant modalities.As part of the ongoing prospective multicentre observational study QCGC 2 (German Gastric Cancer Study 2), 544 adenocarcinomas of the oesophagogastric junction (AEG 1-3) were registered from 01/01/2007 to 12/31/2009.Patients underwent surgical intervention in 108 (76.6 %) of the 141 surgical departments which provided data to the study. In 391 patients (82.5 %), R0 resection was achieved. Almost 60 % of the carcinomas of the oesophagogastric junction were approached in departments with no more than 10 of these tumour lesions through the whole study period (3 years). Endoscopic ultrasonography was performed in 283 cases (53 %); the rate of neoadjuvant treatment was 34.4 % (n = 187). Intraoperative fresh frozen section was only included in intraoperative decision-making in 242 patients (60.8 %). In the revealed heterogeneous spectrum of surgical interventions, a limited number of transthoracic approaches (20 %) and a mediastinal lymphadenectomy rate of only 47 % were found. Hospital lethality was 6.6 %. In the adenocarcinomas of the oesophagogastric junction, a significantly lower median survival (25 months) compared with distal gastric cancer (38 months) was observed depending on the tumour stage. In addition, 5-year survival rate of AEG patients (33.1 %) was distinctly lower than for patients with distal gastric cancer (41.4 %). There was no significantly better survival by neoadjuvant treatment in the group of investigated patients.The results in the treatment of carcinomas of the oesophagogastric junction in the multicentre setting including surgical departments of each profile and region even after introduction of multimodal therapeutic concepts are not satisfying. In particular, modern diagnostic and surgical strategies need to be widely used or their percentage has to be increased. In this context, centralisation of the surgical care of this specific tumour entity appears reasonable. more...
- Published
- 2013
14. [Surgical treatment of gastric carcinoma. German multicenter observational studies]
- Author
-
K, Ridwelski, I, Gastinger, H, Ptok, F, Meyer, H, Dralle, and H, Lippert
- Subjects
Postoperative Complications ,Gastrectomy ,Stomach Neoplasms ,Germany ,Humans ,Multicenter Studies as Topic ,Observation ,Hospital Mortality ,Follow-Up Studies ,Neoplasm Staging - Abstract
The aim of the review is to compare the results of selected German multicenter observational studies on the surgical treatment of gastric carcinoma within the last two decades. Overall, 6,035 patients with gastric cancer who had been registered in numerous German comprehensive surgical clinics and departments in the time periods 1986-1989, January through December 2002 and 2007-2009 were enrolled in this analysis. In particular, the study aimed to investigate the most important criteria and factors with an impact on the perioperative and early postoperative outcome including the effects on oncological long-term results. In addition to the advances in diagnostic procedures and surgical techniques, the impact of multimodal therapeutic concepts which have been established particularly in the third investigation period is emphasized. more...
- Published
- 2013
15. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy : ML18147 study KRAS subgroup findings
- Author
-
S. Kubicka, R. Greil, T. André, J. Bennouna, J. Sastre, E. Van Cutsem, R. von Moos, P. Österlund, I. Reyes-Rivera, T. Müller, M. Makrutzki, D. Arnold, J. Andel, P. Balcke, B. Benedicic, W. Eisterer, M. Fridrik, B. Jagdt, F. Keil, A. Kretschmer, P. Krippl, H. Oexle, M. Pecherstorfer, H. Samonigg, M. Schmid, J. Thaler, C. Tinchon, H. Weiss, J. Arts, M. De Man, G. Demolin, J. Janssens, M. Polus, B. Benczikova, B. Melichar, J. Prausova, P. Vitek, F.Z. Andersen, B.B. Jensen, N. Keldsen, K. Østerlind, K. Vistisen, A. Elme, A. Magi, K. Ojamaa, R. Ristamäki, T. Salminen, M. Ben Abdelghani, O. Bouche, C. Borg, K. Bouhier-Leporrier, G. Breysacher, L. Chone, M.-C. Clavero Fabri, G. Deplanque, F. Desseigne, L.-M. Dourthe, J. Ezenfis, R. Faroux, E. François, C. Garnier, M.-H. Gaspard, M. Hebbar, J.F. Illory, M.-C. Kaminsky, T. Lecomte, J.-L. Legoux, B. Levache, C. Lobry, J.-P. Lotz, M. Mabro, S. Manet-Lacombe, S. Manfredi, T. Matysiak Budnik, L. Miglianico, L. Mineur, I. Moullet, H. Naman, P. Nouyrigat, S. Oziel-Taieb, H. Perrier, D. Pezet, J. Philip, V. Pottier, M. Porneuf, M. Ramdani, D. Re, Y. Rinaldi, D. Spaeth, J. Taieb, E. Terrebonne, P. Texereau, A. Thirot Bidault, C. Tournigand, N. Tubiana-Mathieu, J.-M. Vantelon, F. Viret, M. Ychou, M. Bangerter, M.E. Bertram, B. Bohnsteen, L. Brinkmann, K. Caca, C. Constantin, H.-J. Cordes, G. Dietrich, J. Eggert, E. Engel, J. Fahlke, H. Fensterer, A. Florschütz, G. Folprecht, H. Forstbauer, W. Freier, M. Freund, N. Frickhofen, E. Gäbele, M. Geißler, F. Gieseler, T. Göhler, U. Graeven, M. Groschek, M. Grundeis, U. Hacker, V. Hagen, H.F. Hebart, S. Hegewisch-Becker, M. Heike, T. Herrmann, B. Hildebrandt, H.-G. Höffkes, G. Hübner, J. Hübner, E. Kettner, M. Kneba, J.W. Kohnke, G. Kojouharoff, C. König, A. Kretzschmar, H. Kröning, K. Kürner, F. Lammert, C. Lerchenmüller, A. Lück, J. Meiler, H.-G. Mergenthaler, L. Müller, C. Müller-Naendrup, A. Nusch, J. Papke, R. Porschen, J. Rädle, C. Reddemann, K. Ridwelski, J. Riera-Knorrenschild, J. Rudi, A. Schmalenberger, C.-C. Schimanski, F. Schlegel, C. Schlichting, P. Schmidt, W. Schmiegel, S. Schmitz, H. Schulze-Bergkamen, I. Schwaner, A. Schwarzer, M. Schwerdtfeger, J. Selbach, M. Sieber, J. Siebler, P. Staib, M. Stauch, C.-C. Steffens, P. Stübs, J. Tischendorf, T. Trarbach, D. Tummes, A.-R. Valdix, A. Vogel, G.P.L. Von Wichert, M. Walther, W. Welslau, G. Wilhelm, H. Wobster, T. Wolf, N. Zeigenhagen, B. Zomorodbaksch, E. Batman, H.J. Bloemendal, D.F.S. Kehrer, T. Guren, G. Indrebø, C. Kersten, H. Soerbye, M. Fragoso, R. Fragoso, J.C. Mellidez, A. Sa, A. Aljobran, T. Darwish, V. Alonso-Orduna, J. Aparicio, E. Aranda, C. Bosch, A. Galan-Brotons, I. Busquier Hernandez, J.C. Camara, J.M. Campos Cervera, C. Carlos Garcia Giron, P.M. Del Prado, O. Donnay, P. Escudero, E. Falco, J. Gallego Plazas, P. Garcia Alfonso, E. Gonzalez Flores, C. Gravalos, R. Guardeno, A. Juárez, A. Lopez Ladron, F. Losa Gaspa, J. MªVicent Vergé, E. Marcuello Gaspar, B. Massuti Sureda, J. Molina, I.C. Montero, A.L. Muñoa, M.B. Naranjo, M.J. Oruezabal Moreno, V. Pachón Olmos, C. Pericay, J.J. Reina Zoilo, F. Rivera, A. Ruiz Casado, M.J. Safont, A. Salud Salvia, M. Tobena, J.C. Toral, V. Valenti, M. Valladares Ayerbes, J.M. Vieitez, R. Vera, A. Berglund, E. Fernebro, V. Hess-Umbricht, M. Pless, R. Popescu, R. Winterhalder, and Trarbach, Tanja (Beitragende*r) more...
- Subjects
Adult ,Male ,Vascular Endothelial Growth Factor A ,Oncology ,medicine.medical_specialty ,Survival ,Bevacizumab ,Colorectal cancer ,medicine.medical_treatment ,Medizin ,Antibodies, Monoclonal, Humanized ,medicine.disease_cause ,Disease-Free Survival ,Proto-Oncogene Proteins p21(ras) ,Capecitabine ,Young Adult ,Proto-Oncogene Proteins ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,Biomarkers, Tumor ,medicine ,Humans ,Prospective Studies ,Neoplasm Metastasis ,neoplasms ,Aged ,Aged, 80 and over ,Chemotherapy ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Chemotherapy regimen ,digestive system diseases ,Oxaliplatin ,Surgery ,Treatment Outcome ,Fluorouracil ,ras Proteins ,Female ,KRAS ,Colorectal Neoplasms ,business ,medicine.drug - Abstract
ML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line bevacizumab-containing therapy.Evaluating outcomes according to tumor Kirsten rat sarcoma virus oncogene (KRAS) status was an exploratory analysis. KRAS data were collected from local laboratories (using their established methods) and/or from a central laboratory (mutation-specific Scorpion amplification-refractory mutation system). No adjustment was made for multiplicity; analyses were not powered to detect statistically significant differences.Of 820 patients, 616 (75%) had unambiguous KRAS data; 316 (51%) had KRAS wild-type tumors and 300 (49%) had mutant KRAS tumors. The median progression-free survival (PFS) was 6.4 months for bevacizumab plus chemotherapy and 4.5 months for chemotherapy [P0.0001; HR = 0.61; 95% confidence interval (CI): 0.49-0.77] for wild-type KRAS and 5.5 and 4.1 months, respectively (P = 0.0027; HR = 0.70; 95% CI: 0.56-0.89) for mutant KRAS. The median overall survival (OS) was 15.4 and 11.1 months, respectively (P = 0.0052; HR = 0.69; 95% CI: 0.53-0.90) for wild-type KRAS and 10.4 versus 10.0 months, respectively (P = 0.4969; HR = 0.92; 95% CI: 0.71-1.18) for mutant KRAS. In both analyses, no treatment interaction by KRAS status was observed (PFS, P = 0.4436; OS, P = 0.1266).Bevacizumab beyond first progression represents an option for patients with mCRC treated with bevacizumab plus standard first-line chemotherapy, independent of KRAS status. more...
- Published
- 2013
16. Gastrointestinale Tumore
- Author
-
H. Lang, K. Ridwelski, W. Schmiegel, H.-J. Schmoll, and C. Rdel
- Published
- 2011
- Full Text
- View/download PDF
17. [German S3-guideline 'Diagnosis and treatment of esophagogastric cancer']
- Author
-
M, Moehler, S-E, Al-Batran, T, Andus, M, Anthuber, J, Arends, D, Arnold, D, Aust, P, Baier, G, Baretton, J, Bernhardt, H, Boeing, E, Böhle, C, Bokemeyer, J, Bornschein, W, Budach, E, Burmester, K, Caca, W A, Diemer, C F, Dietrich, M, Ebert, A, Eickhoff, C, Ell, J, Fahlke, H, Feussner, R, Fietkau, W, Fischbach, W, Fleig, M, Flentje, H E, Gabbert, P R, Galle, M, Geissler, I, Gockel, U, Graeven, L, Grenacher, S, Gross, J T, Hartmann, M, Heike, V, Heinemann, B, Herbst, T, Herrmann, S, Höcht, R D, Hofheinz, H, Höfler, T, Höhler, A H, Hölscher, M, Horneber, J, Hübner, J R, Izbicki, R, Jakobs, C, Jenssen, S, Kanzler, M, Keller, R, Kiesslich, G, Klautke, J, Körber, B J, Krause, C, Kuhn, F, Kullmann, H, Lang, H, Link, F, Lordick, K, Ludwig, M, Lutz, R, Mahlberg, P, Malfertheiner, S, Merkel, H, Messmann, H-J, Meyer, S, Mönig, P, Piso, S, Pistorius, R, Porschen, T, Rabenstein, P, Reichardt, K, Ridwelski, C, Röcken, I, Roetzer, P, Rohr, W, Schepp, P M, Schlag, R M, Schmid, H, Schmidberger, W-H, Schmiegel, H-J, Schmoll, G, Schuch, C, Schuhmacher, K, Schütte, W, Schwenk, M, Selgrad, A, Sendler, J, Seraphin, T, Seufferlein, M, Stahl, H, Stein, C, Stoll, M, Stuschke, A, Tannapfel, R, Tholen, P, Thuss-Patience, K, Treml, U, Vanhoefer, M, Vieth, H, Vogelsang, D, Wagner, U, Wedding, A, Weimann, H, Wilke, C, Wittekind, and M, Möhler more...
- Subjects
Esophageal Neoplasms ,Stomach Neoplasms ,Germany ,Gastroenterology ,Humans - Published
- 2011
18. Endorectal ultrasound in rectal carcinoma--do the literature results really correspond to the realities of routine clinical care?
- Author
-
Ingo Gastinger, Hans Lippert, K. Ridwelski, Maik Sahm, Frank Marusch, Uwe Schmidt, and H. Ptok
- Subjects
Endoscopic ultrasound ,medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Rectal Neoplasms ,medicine.medical_treatment ,Ultrasound ,Carcinoma ,Gastroenterology ,Sensitivity and Specificity ,Confidence interval ,Surgery ,Endosonography ,Clinical trial ,Predictive Value of Tests ,Predictive value of tests ,Positive predicative value ,medicine ,Humans ,Radiology ,Prospective Studies ,Prospective cohort study ,business ,Neoadjuvant therapy ,Neoplasm Staging - Abstract
Background and study aims This multicenter, prospective, country-wide quality-assurance study at more than 300 hospitals in Germany was designed to characterize and analyze the diagnostic accuracy of rectal endoscopic ultrasound (EUS) in the routine clinical staging of rectal carcinoma (depth of tumor infiltration). Patients and methods Patients were surveyed between 1 January 2000 and 31 December 2008. Those who received neoadjuvant therapy after EUS were excluded. The correspondence between the EUS assessment of tumor depth (uT) and that determined by histology (pT) was calculated, and the influence of hospital volume upon the sensitivity, specificity, and positive and negative predictive values was investigated. Results At 384 hospitals providing care at all levels, 29 206 patients were included; of the 27 458 treated by surgical resection, EUS was performed for 12 235 (44.6 %). Of these, 7096 did not receive neoadjuvant radiochemotherapy, allowing a uT-pT comparison. The uT-pT correspondence was 64.7 % (95 % confidence interval [CI] 63.6 % - 65.8 %); the frequency of understaging was 18 % (95 %CI 17.1 % - 18.9 %) and that of overstaging was 17.3 % (95 %CI 16.4 % - 18.2 %). The kappa coefficient was greatest in the category T1 (κ = 0.591). For T3 tumors κ was 0.468. The poorest correspondence was found for T2 and T4 tumors (κ = 0.367 and 0.321, respectively). A breakdown by hospital volume showed that the uT-pT correspondence was 63.2 % (95 %CI 61.5 % - 64.9 %) for hospitals undertaking ≤ 10 EUS/year, 64.6 % (95 %CI 62.9 % - 66.2 %) for doing 11 - 30 EUS/year, and 73.1 % (95 %CI 69.4 % - 76.5 %) for those hospitals performing > 30 EUS/year. Conclusions In clinical routine, the diagnostic accuracy of transrectal ultrasound in staging rectal carcinoma does not attain the very good results reported in the literature. Only in the hands of diagnosticians with a large case volume of rectal carcinoma patients can EUS lead to therapy-relevant decisions. more...
- Published
- 2011
19. A Venous Access Mini-Port Implanted on the Proximal Forearm, on the Distal Upper Arm or on the Chest Wall
- Author
-
Wolfgang E. Berdel, K. Ridwelski, M. Matthias, Agnieszka Korfel, B.-M. Harnoss, J. Boese-Landgraf, E. May, and Eckhard Thiel
- Subjects
Cancer Research ,medicine.medical_specialty ,Port (medical) ,medicine.anatomical_structure ,Oncology ,Forearm ,business.industry ,Medicine ,Hematology ,business ,Venous access ,Surgery - Abstract
Background : The main objective of this study was to compare 3 implantation sites for a new mini-port system (Pharmacia Deltec, Erlangen, FRG) on the proximal forearm, on the distal
- Published
- 1993
- Full Text
- View/download PDF
20. [Results of surgical treatment in ampullary and pancreatic carcinoma and its prognostic parameters after R0-resection]
- Author
-
K, Ridwelski, F, Meyer, U, Schmidt, and H, Lippert
- Subjects
Adult ,Aged, 80 and over ,Male ,Ampulla of Vater ,Time Factors ,Anastomosis, Surgical ,Common Bile Duct Neoplasms ,Middle Aged ,Prognosis ,Survival Analysis ,Pancreatic Neoplasms ,Pancreatectomy ,Postoperative Complications ,Humans ,Female ,Gastroenterostomy ,Pancreas ,Aged ,Carcinoma, Pancreatic Ductal ,Neoplasm Staging - Abstract
Resection is currently the only established reasonable therapeutic option with curative potential in pancreatic and ampullary carcinoma. The aim of the study was i) to analyze value and results of surgical therapy and ii) to detect the prognostic parameters, which determine significantly higher survival rates.Two-hundred-twenty patients with pancreatic and ampullary carcinoma (mean age, 61.4 years; 104 females/116 males) underwent surgery. Histologic investigation revealed 19 carcinomas of the papilla of Vater and 201 ductal pancreatic carcinomas. In 126 patients, stage IV a or b tumors were found, in addition, stage I (n =26), II (n = 17) and III (n = 51). Survival-rate was determined according to the method by Kaplan/Meier. Survival was compared using log-rank test. Association of several or multiple parameters with survival was tested using Cox model.Hundred-ten patients underwent tumor resection with primary curative intention (50 %): 96 resections of the pancreatic head, 2 total pancreatectomies and 12 left resections of the pancreas. R0-resection was achieved in 94 patients (42.7 %), whereas intervention was classified R1 in 10 and R2 in 6 cases. In addition, 60 palliative interventions (28 gastroenterostomies, 17 biliodigestive anastomoses, 15 anastomoses at both sites) and 50 explorative laparotomies were performed. In 42.3 % of patients, postoperative complications were found, but only 12/220 individuals died (overall letality, 5.4 %). Postoperative letality of curative pancreatic resections was 3.6 % (palliative intervention, 6.7 %; explorative laparotomy, 8.8 %). Five-year survival-rate of carcinoma of the papilla of Vater and pancreatic carcinoma was 73.3 % and 16.2 %, respectively (median survival time was 66.0 and 14.0 months, respectively). Taken together all other interventions, median survival time ranged between 4.0 (palliative intervention) to 10.0 months (R1-resection). No patient survived 5 years. Therefore, the most relevant prognostic factor was R0-resection. In addition, prognosis after successful R0-resection is determined significantly by tumor site, stage of the tumor (according to UICC), T- and N-category.Resection of pancreatic and ampullary carcinoma according to oncological criteria with tumor-free margins can be considered a treatment option with curative intention and potential. Despite relative high postoperative morbidity, only a low mortality rate was observed. The 5-year survival-rate of 16.2 % in ductal pancreatic carcinoma underlines the demand for the development of effective multimodal therapeutic concepts. Interventions with primary palliative intention or resections with microscopically or macroscopically detectable tumor residual in situ lead to no significant or only marginal prolongation of survival time. Such interventions in patients with pancreatic carcinoma are no reasonable treatment alternative. They are of value only for treatment of tumor-associated complications and problems. more...
- Published
- 2005
21. [Interim analysis of a prospective, randomized multi-center study by the 'Liver Metastases' Study Group: adjuvant intra-arterial chemotherapy after curative liver resection of colorectal metastases]
- Author
-
M, Lorenz, H H, Müller, H, Schramm, H J, Gassel, J, Hauss, K, Ridwelski, and H, Schäfer
- Subjects
Adult ,Male ,Liver Neoplasms ,Leucovorin ,Middle Aged ,Combined Modality Therapy ,Survival Rate ,Chemotherapy, Adjuvant ,Hepatectomy ,Humans ,Infusions, Intra-Arterial ,Female ,Fluorouracil ,Neoplasm Recurrence, Local ,Colorectal Neoplasms ,Colectomy ,Aged ,Follow-Up Studies - Abstract
Recurrence after resection of colorectal liver metastases occurs after 9-12 months in up to 80% of patients. Half of the relapses is isolated to the liver. An intraarterial chemotherapy with 5-FU and folinic acid was compared to only resection. Main objective of the trial was survival. Within 14 days after resection followed the 6-month therapy with 5-FU 1000 mg/m2 continuously over 5d/28d and Folinic Acid 200 mg/m2 over 15 minutes 5d/28d. The first interim-analysis with 226 randomised patients showed in the intention-to-treat-analysis a median survival of 34.5 months (m.) with therapy versus 40.8 months (p = 0.1519 with a negative trend. (95%-Confidence interval for hazard ratio: [0.5; 1.15]) and time to progression of 14.2 m. with therapy versus 13.7 m. Severe toxicities (WHO grade III/IV) occurred in 25.6% of cycles and 62.9% of patients. Mainly registered were stomatitis (57.6%) and nausea (55.4%). The recruitment of patients for study was terminated, because in best case the risk to die could be lowered only by 15% and therefore clinical relevant prolongation of survival is not to achieve with this type of adjuvant therapy. more...
- Published
- 2003
22. [Laparoscopic adrenalectomy--experiences with transperitoneal approach]
- Author
-
M, Pross, T, Manger, F, Heres, S, Klose, H, Lehnert, K, Ridwelski, S, Wolff, R, Mantke, F, Marusch, and H, Lippert
- Subjects
Adult ,Male ,Adrenal Gland Neoplasms ,Adrenalectomy ,Pheochromocytoma ,Length of Stay ,Middle Aged ,Paraneoplastic Endocrine Syndromes ,Outcome and Process Assessment, Health Care ,Postoperative Complications ,Adrenocortical Adenoma ,Humans ,Female ,Laparoscopy ,Peritoneum ,Aged - Abstract
We report our results of laparoscopic anterior transperitoneal adrenalectomy.Between 4/1996 to 05/2001, a laparoscopic adrenalectomy was performed in 34 patients (median age 48 years). The adrenalectomy was performed transperitoneally (31 unilateral; 3 bilateral). The adrenaline level was measured in 7 patients with a pheochromocytoma.All tumors (mean size 3.5 cm; 0.4 to 8.0 cm) could be extirpated by laparoscopy. 9 pheochromocytomas; 9 cortisol producing tumors (one patient with a Carney's syndrome); 7 Conn's adenomas and 9 incidentalomas constituted these tumors. In the first third of the observation period, the surgery lasted 176 (95-270) minutes, in the last third 82 (50-130) minutes (p0,01). We postoperatively observed the following complications: one abdominal wall hematoma at a port-site and one edematous pancreatitis after alteration of the pancreatic tail. The adrenaline level continually rose from the beginning of surgery to the ligature of the suprarenal vein.Transperitoneal adrenalectomy in benign tumors (8 cm) is our method of choice. The resulting learning curve allowed the performance of adrenalectomy within an acceptable operative time and without significant blood loss. The transperitoneal technique is safe and well reproducible. The cosmetical results are convincing. We recommend an early ligature of the suprarenal vein in a pheochromocytoma. more...
- Published
- 2002
23. Primary sarcoma of the inferior vena cava: review of diagnosis, treatment, and outcomes in a case series
- Author
-
K, Ridwelski, S, Rudolph, F, Meyer, P, Buhtz, T, Burger, and H, Lippert
- Subjects
Leiomyosarcoma ,Fatal Outcome ,Treatment Outcome ,Humans ,Female ,Vena Cava, Inferior ,Retroperitoneal Neoplasms ,Middle Aged ,Aged - Abstract
Leiomyosarcoma of the inferior vena cava is a rare mesenchymal tumor. The diagnostic approach, based on general guidelines of oncologic surgery, seems to be relatively routine; specific aspects of treatment, including vascular reconstruction, depend on tumor stage, grade, and location. In this report, the management of this disease in 5 patients is summarized and the literature is reviewed. A thorough diagnostic assessment includes sonography, computed tomography, angiography or duplex ultrasonography, perioperative pathohistologic examination, and appropriate differential diagnosis. Radical resection is associated with the best outcome and long-term survival. In this series, 4 of 5 patients underwent tumor resection. In 2 patients, the disease was classified as R0. Another patient had R1 status found at resection and underwent postoperative radiation after the tumor bed was marked intraoperatively. She has remained stable since treatment. One patient died of pulmonary metastases 32 months after primary R1 tumor resection. The 5th patient has been stable since diagnosis; resection was not possible because of severe accompanying diseases and because consent for surgical intervention could not be obtained from the patient. There is reasonable hope that leiomyosarcoma of the inferior vena cava can be treated successfully, even in advanced stages, with novel antineoplastic drugs and radiotherapeutic protocols. However, general treatment recommendations have not yet been compiled. more...
- Published
- 2002
24. Intra- und frühe postoperative Chemotherapie in die Bauchhöhle mittels Gemcitabine kann das postoperative Auftreten einer Peritonealkarzinomatose verhindern
- Author
-
K. Ridwelski, Frank Meyer, Hans Lippert, and A. Hribaschek
- Abstract
Intra- and Early Postoperative Chemotherapy in the Abdominal Carity by Means of Gemcitabine Can Prevent the Postoperative Occurrence of a Peritoneal Carcinomatosis Hintergrundc Im Fall einer Peritonealkarzinomatose gibt es keine kurative Behandlung fur jeglichen Tumor in der Peritonealhohle. Das Ziel dieser experimentellen Studie bestand darin, das Praventivpotential einer intra- oder fruhen postoperativen lokalen Gemcitabineverabreichung in die Bauchhohle gegen eine Peritonealkarzinomatose zu prufen. Methode: Die Peritonealkarzinomatose wurde in mannlichen WAG-Ratten (n = 18) durch den Transfer von 5 × 1.000.000 Zellen der Adenokarzinom-Zelllinie CC-531 via Minilaparotomie unter Allgemeinanasthesie induziert. Dreisig Tage nach Zelltransfer wurde die Peritonealkarzinomatose post mortem durch histologische Untersuchung an Proben des Peritoneums bestatigt. Die Extension der Karzinomatose wurde mittels i) Zahlen der Tumorknoten pro qcm (Mittelwert mehrfacher Zahlung) und ii) Bestimmung der Tumorgewichts (Gewicht von grosem Netz plus reseziertem Mesenterium) ermittelt. Die Ratten wurden in 3 Gruppen — unterteilt (n = 6 pro Gruppe). Gruppe 1 (Kontrollen); Gruppe 2: Simultan mit dem Tumorzelltransfer intraperitoneal (i.p.) wurden 24 mg/kg Gemictabine verabreicht; Gruppe 3: Postoperative i.p. Irrigation mit 24 mg/kg Gemictabine via vorher implantiertes Portsystem an den Tagen(d) 15,21 & 27. Ergebnisse: Am 30. postoperativen Tag zeigten alle 6 Kontrolltiere ein extensives Tumorwachstum am Peritoneum und grosen Netz, was fur eine Peritoneal-karzinomatose sprach. Dagegen zeigte keines der Tiere aus Gruppe 2 irgendwelche Anzeichen von Tumorwachstum. Wahrend alle Ratten aus Gruppe 3 i.p.-Tumorwachstum aufwiesen, resultierte die fruhe postoperative Behandlung mit Gemcitabine in einer signifikanten Reduktion der Zahl der Lymphknoten und der Tumormasse im Vergleich zu den Kontrollen. Zusammenfassungg: Die unmittelbare, d.h. simultane intraoperative Applikation eines Zytostatikums wie Gemcitabine in die Bauchhohle kann der Ausbildung einer Peritoneal-karzinomatose durch auftretende Tumorzellen vorbeugen, wohingegen die fruhe postoperative lokoregionare Chemotherapie in die Bauchhohle ihre Schwere mindern kann more...
- Published
- 2002
- Full Text
- View/download PDF
25. Inhalt, Vol. 16, 1993
- Author
-
G. Hartung, D. Zeidler, W. Kwasny, M. Schemper, W.E. Berdel, A.L. Hotze, T. Möhler, T. Grant, D. Maclachlan, V. Diehl, S. Seeber, K. Ridwelski, H. Löffler, A. Obermair, K. Czerwenka, N. Niederle, P. Sevelda, H.J. Biersack, P. Brossart, E.K. Walther, E. Thiel, M. Löffler, M. Pfreundschuh, W. Scheithauer, H. Bender, E. Hagmüller, H. Kleinau, E. Colajori, H. Henss, T. Chan, M. Djavanmard, C. Kurz, J. Boese-Landgraf, V. Ray, B. Lathan, G.G.T.Y. Chen, L. Uharek, W. Queißer, M. Matthias, K. Haider, P. Ray, M. Tiemann, P. Diezler, A. Korfel, C. Scheibenbogen, P.M. Schlag, B.-M. Harnoss, W. Gassmann, D. Depisch, W. Eberhardt, D. Hasenclever, E. Dühmke, H. Tesch, J. Alberty, A. Schomburg, R. Engelhardt, S. Kerpel-Fronius, A. Engert, C. Herberhold, P. Chiru, E. May, M. Raderer, H. Wilke, B. Weidmann, W. Hunstein, S. Vijayakumar, U. Liebeskind, T. Haferlach, U. Keilholz, and M. Zaiac more...
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 1993
- Full Text
- View/download PDF
26. Contents, Vol. 16, 1993
- Author
-
P. Brossart, E. Thiel, P. Diezler, A. Korfel, T. Möhler, W. Scheithauer, G.G.T.Y. Chen, A. Obermair, K. Czerwenka, N. Niederle, W. Hunstein, D. Zeidler, W. Kwasny, W. Gassmann, M. Schemper, S. Vijayakumar, H. Henss, D. Maclachlan, U. Liebeskind, C. Kurz, E.K. Walther, H. Bender, C. Scheibenbogen, T. Grant, P. Ray, P.M. Schlag, T. Haferlach, K. Haider, J. Boese-Landgraf, H.J. Biersack, U. Keilholz, M. Tiemann, G. Hartung, L. Uharek, A.L. Hotze, E. Colajori, M. Zaiac, W. Queißer, M. Raderer, H. Wilke, H. Löffler, V. Diehl, B. Weidmann, K. Ridwelski, P. Sevelda, W.E. Berdel, E. Hagmüller, M. Djavanmard, T. Chan, V. Ray, B. Lathan, B.-M. Harnoss, C. Herberhold, M. Matthias, P. Chiru, M. Pfreundschuh, S. Seeber, M. Löffler, H. Kleinau, W. Eberhardt, R. Engelhardt, S. Kerpel-Fronius, A. Engert, E. May, E. Dühmke, H. Tesch, A. Schomburg, D. Depisch, D. Hasenclever, and J. Alberty more...
- Subjects
Cancer Research ,Oncology ,Hematology - Published
- 1993
- Full Text
- View/download PDF
27. Subject Index 1993
- Author
-
H. Kleinau, R. Engelhardt, T. Chan, S. Kerpel-Fronius, A. Engert, A. Obermair, K. Czerwenka, E. May, W. Gassmann, V. Diehl, W. Scheithauer, E. Hagmüller, H. Henss, C. Kurz, S. Seeber, G.G.T.Y. Chen, A. Schomburg, P. Ray, M. Löffler, M. Pfreundschuh, P.M. Schlag, M. Matthias, W. Hunstein, J. Boese-Landgraf, K. Haider, S. Vijayakumar, T. Grant, D. Maclachlan, U. Liebeskind, D. Zeidler, W. Eberhardt, E.K. Walther, W. Kwasny, H. Bender, W.E. Berdel, M. Schemper, H.J. Biersack, E. Colajori, M. Tiemann, A.L. Hotze, M. Raderer, P. Sevelda, H. Wilke, M. Djavanmard, N. Niederle, G. Hartung, B. Weidmann, T. Haferlach, U. Keilholz, D. Depisch, J. Alberty, M. Zaiac, D. Hasenclever, E. Dühmke, H. Tesch, C. Herberhold, P. Chiru, C. Scheibenbogen, L. Uharek, W. Queißer, V. Ray, K. Ridwelski, P. Brossart, H. Löffler, E. Thiel, B.-M. Harnoss, P. Diezler, A. Korfel, T. Möhler, and B. Lathan more...
- Subjects
Cancer Research ,Index (economics) ,Oncology ,Statistics ,Subject (documents) ,Hematology ,Mathematics - Published
- 1993
- Full Text
- View/download PDF
28. [Value of cytokeratin and Ca 19-9 antigen in immunohistological detection of disseminated tumor cells in lymph nodes in pancreas carcinoma]
- Author
-
K, Ridwelski, F, Meyer, J, Fahlke, U, Kasper, A, Roessner, and H, Lippert
- Subjects
Adult ,Male ,Ampulla of Vater ,CA-19-9 Antigen ,Carcinoma ,Common Bile Duct Neoplasms ,Adenocarcinoma ,Middle Aged ,Prognosis ,Immunohistochemistry ,Pancreatic Neoplasms ,Pancreatitis ,Predictive Value of Tests ,Lymphatic Metastasis ,Chronic Disease ,Biomarkers, Tumor ,Humans ,Keratins ,Female ,Lymph Nodes ,Aged ,Neoplasm Staging - Abstract
Based on the fact that pancreatic carcinoma is still associated with poor outcome, the aim of the study was to determine frequency of early tumor cell dissemination using immunohistology in lymph nodes classified as tumor-free by conventional histopathology.Fifteen patients with ductal pancreatic carcinoma and 10 patients with carcinoma of the papilla of Vater underwent radical tumor resection (resection status R0, tumor staging pTxpN0M0). In total, 229 lymph nodes classified as tumor-free by histopathology were investigated for disseminated tumor cells using antibodies against cytokeratin and CA19-9. As control, 81 lymph nodes obtained from patients with chronic pancreatitis were analyzed.In 55 of 229 lymph nodes (26.3%), cytokeratin-positive, disseminated tumor cells were detected. Cytokeratin-positive cells were found in at least one resected lymph node of each patient with ductal carcinoma of the pancreatic head (100%), whereas in patients with carcinoma of the papilla of Vater, no disseminated tumor cells were detected using the antibody against cytokeratin. Similarly, there was no detection of tumor cells (false-positive) in patients with chronic pancreatitis. In contrast, CA19-9 antigen was detectable in resected lymph nodes of each of the 25 carcinoma patients (pancreatic carcinoma and carcinoma of the papilla of Vater). Interestingly, 52 of 81 lymph nodes (64.2%) from the control group (chronic pancreatitis) were false-positive.Detection of disseminated tumor cells in lymph nodes using an antibody against cytokeratin is specific and suitable while use of an antibody against CA19-9 is not recommendable because of the high rate of false-positive results. The results may indicate that ductal pancreatic carcinoma generates early dissemination of tumor cells into lymph nodes. This may be one explanation for the poor outcome of this carcinoma compared with that of the carcinoma of the papilla of Vater (14 versus 48 months P0.05). more...
- Published
- 2001
29. [Hepatobiliary cystadenoma]
- Author
-
R, Mantke, K, Ridwelski, C, Röcken, M, Pross, H U, Schulz, and H, Lippert
- Subjects
Adult ,Echinococcosis, Hepatic ,Cystadenoma ,Liver Neoplasms ,Middle Aged ,Diagnosis, Differential ,Bile Ducts, Intrahepatic ,Bile Duct Neoplasms ,Liver ,Hepatectomy ,Humans ,Female ,Tomography, X-Ray Computed ,Aged - Abstract
Hepato-biliary cystadenomas are rare intrahepatic cystic tumours. The correct preoperative diagnosis of this lesion is difficult.We report four cases of hepato-biliary cystadenoma treated in our department from January 1995 to December 1999.The symptoms were unspecific. Preoperative computed tomography showed signs of an echinococcal cystic lesion in two patients, but there were no antibodies against an echinoccocal species in the serum. We performed a complete resection of the cystic tumour in three patients and a subtotal resection of a hepato-biliary cystadenoma in one, because of involvement of the hepatic portal structures. We did not find a malignant transformation to a hepato-biliary cystadenocarcinoma.Complete excision of a cystadenoma with a wide margin of normal liver tissue is the treatment of choice, because several reports have described malignant transformation of this kind of tumour. Taking a rapidly frozen section during the operation is an important step in the treatment of cystic liver lesions. A cystic liver lesion with several walls and a elevated CA 19-9 can predict a mucinous cystadenoma or cystadenocarcinoma. more...
- Published
- 2001
30. Diagnostic workup before laparoscopic cholecystectomy--which diagnostic tools should be used?
- Author
-
J, Fahlke, K, Ridwelski, T, Manger, R, Grote, and H, Lippert
- Subjects
Adult ,Male ,Gastrointestinal Diseases ,Biliary Tract Diseases ,Gallbladder ,Gallstones ,Middle Aged ,Sensitivity and Specificity ,Cholecystectomy, Laparoscopic ,Risk Factors ,Gastroscopy ,Preoperative Care ,Humans ,Female ,Prospective Studies ,Biliary Tract ,Digestive System ,Cholangiography ,Aged ,Ultrasonography - Abstract
A prerequisite for successful laparoscopic cholecystectomy is the exclusion of potential risks such as cholangiolithiasis, anatomical malformations or diseases of the stomach. As there is no general agreement regarding the appropriate preoperative diagnostic workup, we compared different diagnostic methods as to their value in detecting unknown accompanying diseases and complications.Between 9/90 and 8/93, we performed 850 laparoscopic cholecystectomies. The first 700 were included in this study. A prospective comparison was carried out of the diagnostic accuracy of history, physical examination, laboratory tests, upper gastrointestinal endoscopy or barium meal, i.v. cholangiography and abdominal ultrasound.Measurement of the diameter of the common bile duct was found to be a good noninvasive method for diagnosing common bile duct stones (sensitivity 80%, specificity 99%). In combination with the history and the laboratory tests the sensitivity could be improved to 99%. The sensitivity of i.v. cholangiography in detecting common bile duct stones was 80%, the specificity 99.3%. 646/700 patients underwent preoperative endoscopy/barium meal. In 53 (8.2%) patients pathological findings were found, but only in 4 cases (0.6%) they influenced the indication for laparoscopic cholecystectomy. In 1 patient an advanced gastric cancer was diagnosed 6 months after laparoscopic cholecystectomy, the preoperative barium meal did not show any pathological findings.The results show that routine ultrasonography in combination with history and laboratory tests prior to laparoscopic cholecystectomy can be recommended for detecting common bile duct stones. In patients with 1 or more pathologic finding endoscopic retrograde cholangiopancreatography should be performed preoperatively. A gastroscopy should be done in patients with nonspecific upper abdominal pain, history of peptic ulcer disease and persisting pain after laparoscopic cholecystectomy. more...
- Published
- 2001
31. [Therapy of advanced stomach carcinoma. Current study concepts]
- Author
-
R, Kuhn and K, Ridwelski
- Subjects
Survival Rate ,Stomach Neoplasms ,Antineoplastic Combined Chemotherapy Protocols ,Palliative Care ,Humans ,Combined Modality Therapy ,Neoadjuvant Therapy ,Randomized Controlled Trials as Topic - Abstract
Patients with gastric cancer have a poor prognosis. Only in early tumorstadium a tumor-free-resection is possible. Because curative surgery is often impossible or extremely difficult and the majority of patients undergoing curative resection relapse. To improve this situation adjuvant and neoadjuvant concepts necessary to check. Current adjuvant therapy regimes have a marginal importance. Only nodal positive patients (T3N2M0) may profit from an adjuvant therapy. Neoadjuvant concepts seem to be very effective. The activity is proving in two current studies. Several combination chemotherapy regimens have been developed with activity in locally advanced and metastatic disease. But only an overall survival in median of about 11 month could be reached and a standard protocol not exists. Therefore many studies are initiated. In the follow article three study concepts with new substances especially with Taxanes and with CPT-11 having a great potential to improve the prognosis of patients with advanced gastric cancer are explained. more...
- Published
- 2001
32. Disseminierte Tumorzellen in Lymphknoten beim Pankreaskarzinom — Bedeutung des immunhistologischen Nachweises von Cytokeratin- und CA19-9-Antigen / Disseminated Tumor Cells in Lymph Nodes of the Pancreatic Carcinoma: Immunhistologic Detection of Cytokeratin and CA19-9 Antigen
- Author
-
K. Ridwelski, U. Kasper, B. Matthies, H. Lippert, Albert Roessner, and F. Meyer
- Subjects
Cytokeratin ,Antigen ,business.industry ,Immunology ,Medicine ,Tumor cells ,CA19-9 ,Pancreatic carcinoma ,Lymph ,business ,Molecular biology - Abstract
Ziel war, die Haufigkeit einer Tumor(Tu)zelldissemination in histopathologisch als tumorfrei klassifizierten Lymphknoten (LK) durch Immunhistologie (Ak gegen Cytokeratin und CA19-9) zu bestimmen. Patienten mit duktalem Pankreas- (n=15) und Papillen-Ca (n=10) wurden chirurgisch radikal reseziert (pTxN0M0 R0; nges=229 LK; Kontrolle: n=81 LK von Patienten mit chronischer Pankreatitis). 55 von 229 LK (26,3%) wiesen disseminierte Tu-Zellen auf (Cytokeratin-positiv), wobei bei allen (100%) mit Pankreaskopf-Ca mindestens 1 LK derartige Tu-Zellen aufwies (Papillen-Ca keine Tu-Zellen/chronische Pankreatitis: kein falsch-positiver Befund — spezifisch/sicher). Hingegen wurde bei allen 25 Ca-Patienten ein positiver CA19-9 — Ag-Nachweis in den LK gefuhrt (Kontrolle: 52 von 81 LK [64,2%] falsch-positiv — nicht geeignet). Das heist, das Pankreas-Ca scheint fruher subklinische LK-Metastasen zu bilden. more...
- Published
- 2001
- Full Text
- View/download PDF
33. Esophageal perforation: is minimally invasive treatment possible?
- Author
-
M, Pross, K, Ridwelski, R, Mankte, G, Weiss, and H, Lippert
- Subjects
Aged, 80 and over ,Cholangiopancreatography, Endoscopic Retrograde ,Esophageal Perforation ,Thoracoscopy ,Drainage ,Humans ,Minimally Invasive Surgical Procedures ,Female ,Stents ,Esophagoscopy ,Aged - Published
- 2000
34. [Acute upper gastrointestinal hemorrhage as a complication of hepatic artery port catheter]
- Author
-
F, Reiher, K, Ridwelski, M, Pross, and H, Lippert
- Subjects
Vascular Fistula ,Duodenum ,Liver Neoplasms ,Aneurysm, Ruptured ,Middle Aged ,Embolization, Therapeutic ,Neuroendocrine Tumors ,Catheters, Indwelling ,Hepatic Artery ,Antineoplastic Combined Chemotherapy Protocols ,Intestinal Fistula ,Humans ,Infusions, Intra-Arterial ,Female ,Gastrointestinal Hemorrhage ,Ligation ,Aneurysm, False - Abstract
We report a case of a 56-year-old patient with an acute upper gastrointestinal bleeding following penetration of an aneurysm of the gastroduodenal artery in the duodenal bulb. The patient received an i.a. portsystem five month before the reported acute gastrointestinal bleeding. The portsystem was implanted for treatment of multiple liver metastases of an neuroendocrine tumor. This life-threatening situation could not controlled endoscopically. Also an embolisation was impossible so we carried out a laparotomy with ligation of the proper hepatic artery. The postoperative course was uneventful. Due to her tumor disease the patient died 13 month after surgery. more...
- Published
- 2000
35. Chirurgische Therapieverfahren bei Tumoren der Papilla Vateri
- Author
-
J. Fahlke, K. Ridwelski, H. Lippert, L. Mirow, and M. Pross
- Abstract
Die diagnostische Schwierigkeit bei Tumoren der Papilla Vateri wird deutlich, da in zuvor histologisch gesicherten Adenomen 30–60% Karzinome gefunden werden. In der Zeit von Januar ’94 bis Marz 2000 wurden 25 Patienten mit einer Neubildung im Bereich der Papille operativ behandelt. Anhand dieses Patientengutes stellen wir unser diagnostisches und therapeutisches Konzept (mod. Stufenschema nach Stolte) vor. Danach sind aus den Tumoren mindestens 5–10 Forcepsbiopsien zu entnehmen. Bei nachgewiesener Malignitat ist die Operation nach Kausch-Whipple die einzige therapeutische Option, ebenso beim Adenom > 1 cm. Hat ein Adenom einen Durchmesser unter 1 cm, besteht die Moglichkeit zur transduodenalen Ampullenektomie mit Reinsertion von D. choledochus und pancreaticus, welcher sich bei intraoperativem Malignitatsnachweis wiederum die Whipple-OP anschliest. more...
- Published
- 2000
- Full Text
- View/download PDF
36. Prevention of Port-Site Recurrences: Role of Therapeutic Pneumoperitoneum
- Author
-
K. Ridwelski, M. Pross, and M. A. Reymond
- Subjects
medicine.medical_specialty ,Peritoneal surface ,medicine.diagnostic_test ,business.industry ,Port site ,Cancer ,Peritonitis ,Abdominal cavity ,medicine.disease ,Surgery ,body regions ,Therapeutic pneumoperitoneum ,medicine.anatomical_structure ,medicine ,business ,Laparoscopy ,Mesothelial Cell - Abstract
The automated carbon dioxide (CO2)-pneumoperitoneum was introduced by Semm in 1980 and is now the accepted standard for exposing the abdominal cavity during laparoscopic procedures (Semm 1980). In the meantime, CO2-pneumoperitoneum has been demonstrated to have several side effects. In particular, it has recently been documented that CO2 stimulates tumor growth after laparoscopy for cancer (Jones et aI. 1995a), and that it increases bacterial translocation in peritonitis (Bloechle et al. 1998). CO2 pneumoperitoneum induces a severe acidosis at the peritoneal surface in the animal model (Shah et al., SAGES meeting 1999) and causes morphological changes in mesothelial cells (Bloechle et al. 1999). more...
- Published
- 2000
- Full Text
- View/download PDF
37. Pathogenesis: Transportation of Tumor Cells in Clinical Studies
- Author
-
M. A. Reymond, M. Pross, and K. Ridwelski
- Subjects
Abdominal wall ,Pathogenesis ,medicine.medical_specialty ,medicine.anatomical_structure ,business.industry ,Percutaneous endoscopic gastrostomy ,medicine.medical_treatment ,Medicine ,Staging laparoscopy ,Tumor cells ,Abdominal cavity ,Radiology ,business - Abstract
The exact mechanisms responsible for the development of port-site recurrences within the abdominal wall are still unclear. Such abdominal wall recurrences can occur or not in close proximity with the tumor. In any case, it has to be assumed that, for a port-site recurrence to develop, tumor cells must be present within the abdominal cavity (or disseminated during surgery by various mechanisms), and transported into the site of recurrence (hereafter the port-site), where these cells finally find conditions for growth. more...
- Published
- 2000
- Full Text
- View/download PDF
38. Hepatic and retroperitoneal tumor resection for late metastases of a Wilms' tumor in an adult patient--a case report
- Author
-
R, Mantke, T, Manger, K, Ridwelski, V, Aumann, M, Pross, H U, Schulz, and H, Lippert
- Subjects
Adult ,Male ,Pancreatic Neoplasms ,Time Factors ,Liver Neoplasms ,Hepatectomy ,Humans ,Retroperitoneal Neoplasms ,Combined Modality Therapy ,Wilms Tumor - Abstract
Hepatic metastases after a Wilms' tumor in adult patients are seen extremely rarely. A 21 year-old male patient developed liver metastases 13 years after resection of a primary left extrarenal Wilms' tumor. In this case, without any other metastases, extended right curative hepatic lobectomy was performed. The patient was re-admitted 4 months after the hepatic lobectomy for a resection of a new Wilms' tumor metastatic mass in the area of the pancreatic tail. The patient received adjuvant high dose systemic chemotherapy with ordinary bone marrow cell rescue after the 2nd operation. He is alive and well with no signs of new metastases 18 months after surgery and adjuvant chemotherapy. more...
- Published
- 1999
39. Hepatic artery aneurysm associated with upper gastrointestinal bleeding after intrahepatic artery chemotherapy
- Author
-
M, Pross, K, Ridwelski, F, Reiher, and H, Lippert
- Subjects
Catheters, Indwelling ,Hepatic Artery ,Liver Neoplasms ,Humans ,Infusions, Intra-Arterial ,Antineoplastic Agents ,Female ,Carcinoid Tumor ,Aneurysm, Ruptured ,Middle Aged ,Gastrointestinal Hemorrhage - Abstract
We present the course of illness of a 56 year-old patient with acute gastrointestinal bleeding after penetration of an aneurysm of the hepatic artery in the duodenal bulb. A diffuse intrahepatic metastasis of a carcinoid was treated with a loco-regional intraarterial chemotherapy via a catheter system implanted in the gastroduodenal artery. Five months after the catheter implantation melena occurred. The gastrointestinal arterial bleeding from the penetrating aneurysm presented a life-threatening situation. This cause of bleeding could not be brought under control endoscopically. Immediate surgical management became necessary. more...
- Published
- 1999
40. [Recommendations for adjuvant chemo- and hormone therapy of breast carcinoma]
- Author
-
K, Ridwelski and J, Fahlke
- Subjects
Survival Rate ,Treatment Outcome ,Antineoplastic Agents, Hormonal ,Lymphatic Metastasis ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Breast Neoplasms ,Female ,Prognosis ,Neoadjuvant Therapy - Abstract
Recommendations for adjuvant treatment of patients with breast cancer are given based on the International Consensus panel of adjuvant Therapy of Breast Cancer in St. Gallen in 1998. Possible therapeutical options (antihormonal therapy, chemotherapy with CMF or EC/AC) are discussed in dependence on the risc of recurrence. Problems of individual therapeutical strategies are discussed additionally. more...
- Published
- 1999
41. [Locoregional and systemic therapy of advanced pancreatic carcinoma]
- Author
-
T, Gebauer, K, Ridwelski, J, Fahlke, and H, Lippert
- Subjects
Male ,Pancreatic Neoplasms ,Survival Rate ,Antineoplastic Combined Chemotherapy Protocols ,Palliative Care ,Humans ,Infusions, Intra-Arterial ,Female ,Middle Aged ,Neoplasm Staging - Abstract
Pancreatic cancer has a very poor prognosis despite surgical resection or chemotherapy. For patients with a pancreatic cancer stage III or IV, locoregional or systemic chemotherapy is often the only chance for treatment. In our opinion, locoregional treatment is currently the best concept. more...
- Published
- 1999
42. Subject Index Vol. 53, 2007
- Author
-
A. Hribaschek, Toshiyuki Suzuki, Karsten Ridwelski, Hiroya Takami, Yoshikazu Gotoh, Yuichi Tanaka, Susumu Sueyoshi, Pan Wang, J.C. Rodríguez, J. Fahlke, Quanhong Liu, Frank Meyer, Zerrin Yulugkural, G. Royo, Hiroyasu Makuuchi, Fiona Walsh, Iris Spiliopoulou, H. Lippert, Sotaro Sadahiro, Matthias Pross, Seiei Yasuda, Sofia Zografou, Hiroko Sasahara, Sebastian G. B. Amyes, T. Deist, George Dimitracopoulos, Regine Schneider-Stock, Simon Bracher, Toshiaki Tanaka, Hussien O. AlKadi, Maja A. Hofmann, E. García-Pachon, Chieko Murayama, Naoki Mori, Felix Kiecker, Lina Xiao, T. Nagano, I. Escribano, Xiaobing Wang, Phil Turner, B. Llorca, Akemi Kamijo, Uwe Trefzer, Myrto Christofidou, Kenji Ishikawa, Wolfram Sterry, Hans Lippert, C. Schmidt, M. Ruiz, K. Ridwelski, Hiromichi Gotoh, Verena Gabriel, Yuji Maeda, Amalia Goula, Hideaki Yamana, E. Kettner, K. Hribaschek, Haluk Vahaboglu, D. Quietzsch, P. Stuebs, Annett Milling, Rajesh Pandey, Gopal K. Khuller, Shinichiro Akiyama, M.L. Pereira, M. Assmann, Yoichi Tanaka, Sıla Akhan, Hidetsugu Nakayama, Kazuo Shirouzu, Hiromasa Fujita, U. Keilholz, and F. Garcia e Costa more...
- Subjects
Pharmacology ,Infectious Diseases ,Index (economics) ,Oncology ,Drug Discovery ,Statistics ,Pharmacology (medical) ,Subject (documents) ,General Medicine ,Mathematics - Published
- 2007
- Full Text
- View/download PDF
43. Lokoregionäre und systemische Therapie beim fortgeschrittenen Pankreaskarzinom
- Author
-
T. Gebauer, J. Fahlke, H. Lippert, and K. Ridwelski
- Subjects
Oncology ,Surgical resection ,medicine.medical_specialty ,Chemotherapy ,Poor prognosis ,Systemic chemotherapy ,business.industry ,medicine.medical_treatment ,medicine.disease ,Pancreatic Cancer Stage III ,Pancreatic cancer ,Internal medicine ,medicine ,business - Abstract
Pancreatic cancer has a very poor prognosis despite surgical resection or chemotherapy. For patients with a pancreatic cancer stage III or IV, locoregional or systemic chemotherapy is often the only chance for treatment. In our opinion, locoregional treatment is currently the best concept. more...
- Published
- 1998
- Full Text
- View/download PDF
44. Weekly paclitaxel with epirubicin as second-line therapy of metastatic breast cancer: results of a clinical phase II study
- Author
-
U, Köhler, S S, Olbricht, G, Fuechsel, E, Kettner, B, Richter, and K, Ridwelski
- Subjects
Adult ,Paclitaxel ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Breast Neoplasms ,Middle Aged ,Neoplasm Metastasis ,Aged ,Epirubicin - Abstract
Phase I/II trials have shown that combination of an anthracycline with paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) represents a high-potency therapy for treatment of patients with metastatic breast cancer, with response rates exceeding 90%. This phase II trial was conducted to test the tolerability and efficacy of weekly epirubicin plus paclitaxel as second-line therapy for patients with pretreated metastatic breast cancer. In this study, 35 patients with previous hormone therapy and/or chemotherapy were treated at a weekly dose of paclitaxel 80 mg/m2 with epirubicin 35 mg/m2 (10 patients, 123 cycles) or paclitaxel 80 mg/m2 with epirubicin 25 mg/m2 (25 patients, 218 cycles). The dose reduction of anthracyclines became necessary due to severe hemotoxicity (neutropenia World Health Organization grade 3 to 4 in 30.2% of cycles). The therapy schema included a 2-week therapy interval after each treatment period of 6 weeks, with treatment continued until response or disease progression. Overall, 18 patents (51.4%) presented with responses (complete response or partial response) to therapy, with seven (20%) achieving a complete response after six to 18 cycles. In three cases (8.6%), tumor state was unchanged for a median interval of 11 weeks (range, 5 to 20 weeks). Progressive disease was observed in seven cases (20%), and seven patients (20%) were not evaluable. Following epirubicin dose reduction, neutropenia World Health Organization grade 3 to 4 occurred in only 18.1% of cycles. Referring to nonhematologic toxicity, alopecia exceeded World Health Organization grade 2. Other nonhematologic toxicities exceeding grade 2 were observed in only a few courses and were not statistically relevant. No clinically relevant deterioration of cardiac function was observed at a median cumulative dose of epirubicin 285 mg/m2 (maximum cumulative dose, 630 mg/m2). This study has substantiated that the schedule used is highly efficient and well tolerated as second-line chemotherapy for patients with metastatic breast cancer. more...
- Published
- 1997
45. [Multimodal therapy concept in metastatic carcinoid of the gastrointestinal tract]
- Author
-
R, Mantke, K, Ridwelski, T, Manger, and H, Lippert
- Subjects
Survival Rate ,Treatment Outcome ,Quality of Life ,Humans ,Carcinoid Tumor ,Neoplasm Metastasis ,Combined Modality Therapy ,Follow-Up Studies ,Gastrointestinal Neoplasms - Abstract
Carcinoid tumors are very rarely seen. We have treated 10 patients with carcinoid tumors in the last 4 years. We used arterial chemo-embolisation, embolisation, hepatic arterial ligature and a drug therapy with octreotide and interferon alpha after the resection of the primary tumor. more...
- Published
- 1997
46. TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)
- Author
-
Alain Duhamel, A. Tsuburaya, Mali Okada, S. Kuwabara, H. Hasegawa, A.L. Cohn, Anne Thirot-Bidault, J.R. Delgado, O.U. Unal, J. Isaacson, S. Khudayorov, Sue Ward, N. Mueller, Riccardo Lencioni, Giovanni Abbadessa, D. Takahari, T. Watanabe, Luca Faloppi, Y. Hamamoto, Julia Hocke, Elwyn Loh, M. Aizawa, E. Trejo, A. Novarino, A. Ohtsu, K. Okita, M.J. Flor, Riccardo Giampieri, C. Rose, D. Gonzalez-De-Castro, H. Isayama, M. Esaki, Jean-Pierre Bronowicki, S. Cereda, S. Hironaka, A. Sawaki, I. Iwanicki-Caron, L. Ferrari, J. Stephenson, F. Gerevini, E. Francois, T. Okusaka, S. De Minicis, Cristian Loretelli, S.Y. Roh, A. González-Vicente, F. Richard, H. Tuyev, A. Laforest, K. Lin, M. Milic´evic´, Chunming Li, Wolfgang Eisterer, P. Basile, Mohamed Gasmi, S. Hazama, M. Botta, Seiji Kawazoe, Jean-Luc Raoul, Y. Jiang, I. Trouilloud, B. Nagy, E. del Valle, Satoshi Yuki, K.W. Park, Hanno Riess, M. Bartosiewicz, L. Rolfe, H. Fang, E. Gardner, A. Benedetti, A. Carrato, E. Vasile, Takayuki Kii, N. Suzuki, Y. Shimada, S.F. Ang, S. Fushida, V. Vaccaro, Y. Liu, E. Castanon Alvarez, Y. Ozaki, D. Mirabelli, Ozgur Ozyilkan, J.E. Battley, C.H.S. Kim, N. Weijl, B. Bui, J.C. Sabourin, M. Hejna, Raymond Miller, N. Besova, Jinhui Xu, Ian Chau, J.-L. Van Laethem, Eric Vibert, Philippe Mathurin, H. Yabusaki, Melissa Frizziero, J. Soberino García, S. Salvagni, M. Zhu, Christoph Schuhmacher, Y. Yamada, A. Hubert, R. Libener, S.T. Dimoudis, Jonathan Wadsley, J. Martinez-Galan, Coskun U, V. Karavasilis, Cem Parlak, N. Jain, T. Gamucci, Elisa Giovannetti, R. Gupta, Suleyman Buyukberber, Jose Javier Sanchez, Taro Tokui, Kenneth K. Tanabe, V. Nerich, G. Dyson, Y. Kawachi, J. Reis-Filho, Junichi Sakamoto, A. Mohar-Betancourt, Masahide Mori, Aytug Uner, S. Martin Algarra, C.-J. Yen, J.J. Critchfield, Y. Naomoto, Julien Taieb, Young Seon Hong, Hironori Yamaguchi, S. Jiao, Alan P. Venook, C. Pericay, R.H. Wilson, D. Ferrari, Peter R. Galle, S. Falcon, Emilio Bria, L. Paz-Ares, Anna Tomezzoli, S. Al-Batran, G. Luppi, Jean-Marie Boher, I. Park, F. De Vita, Roland Leung, M. Abdelwahab, A. Ravaioli, Takuya Suzuki, C. Szczylik, C. González-Rivas, Sarita Dubey, Y. Miyashita, J.Y. Lim, Y. Chen, F. El Hajbi, Ichinosuke Hyodo, Tsutomu Chiba, C. Kondo, S. Ye, Thomas Aparicio, M. Nesrine, T. Ganten, T. Nishina, G. Grazi, A.C. Dupont-Gossard, I. Oze, F. Nosrati, J.H. Yook, C. Yoo, N.A. Adu-Aryee, M. Choi, Narikazu Boku, P. Chan, John Bridgewater, A. Gimenez-Capitan, Hamim Zahir, R. Hela, T. Villegas, Stefano Barbi, György Bodoky, D. Degiovanni, Y. Honma, A. Croitoru, K. Koufuji, Lorenza Rimassa, A. Tsuji, Yueyang Shen, Nathan Bahary, S. Abdelwahab, N. Matsuura, Parsee Tomar, L. Yu, Mohammed Elbassiouny, B. Ryoo, S. Adachi, Jean-Robert Delpero, V.D.N.K. Vanderpuye, S.T. Oh, E. Samantas, Amit Bahl, N. Karachaliou, Thierry Lecomte, S. Yoshino, H. Hahn, A. Matsuki, K. Nakamura, D.S. Johnston, M. Del Prete, Per Stål, R. Greil, Dirk Arnold, K. Ridwelski, J. Zhao, K. Shirouzu, Meltem Baykara, G. De Manzoni, I. Lang, K. Aoyagi, A. Fukutomi, Joji Kitayama, Antonieta Salud, K. Beecham, Y. Inoue, Armando Santoro, R. Rosell, P. Malfertheiner, Tsutomu Fujii, Jeong-Yeol Park, S. Taylor, K. Nakajima, Matus Studeny, H. Jiang, M. Shimada, O. Abdelrhman, Camillo Porta, P. Ballesteros, S. Lecleire, K. Han, G. Svegliati Baroni, Michitaka Nagase, François Paye, W. Rodriguez Pantigoso, M.M. Eatock, H.C. Toh, M. Ikeda, Hironori Ishigami, N. Stankovic, H. Kumada, K. Shitara, X. Zhang, E. Arevalo, R. Poon, M. Allard, Y.-Y. Lin, D. Egamberdiev, Shin'ichi Miyamoto, P. Afchain, Harpreet Wasan, Mitesh J. Borad, J. Blay, Dong Sup Yoon, H. Kawai, L. Jin, Margaret Sheehan, T. Otsuji, M. Lichinitser, Ahmet Ozet, R. Savage, Heind Smith, L. Zubiri, Tim Meyer, Erkan Topkan, Ross C. Donehower, Joanne Chiu, T. Tsuda, P. Jimenez Fonseca, U. Selek, N. Musha, B. Liu, A. Magnusson, S.C. Sharma, C. Purcell, H. Wong, E. Lucchini, Jean-Marc Phelip, E. Jeon, J. Fujita, Kelly S. Oliner, W. Schelman, W. Mao, S. Hato, A-L Cheng, D.-L. Ou, Tarek Sahmoud, J. Waters, Jorge A. Marrero, David Malka, P. Xavier, M. Haibo, S. Takiguchi, Q. Pan, S. Ohkawa, J. Kizaki, I.P. Le, A. Roveta, D.H. Koo, H.J. Kim, H. Choi, T. Göhler, A. Gelibter, C. Borg, X. Qiang, Masaya Suenaga, Ozan Cem Guler, Niall C. Tebbutt, M. Emi, S. Ota, N. Nagata, S. Iwasa, Mira Ayadi, K. Matsuo, Henk M.W. Verheul, Christoph C. Zielinski, S. Choo, M.W. Büchler, René Adam, M. Pistelli, J.A. Gonzalez, Charles S. Fuchs, G. Vallati, G. Pentheroudakis, S. Tokunaga, U. Demirci, Lin Shen, B. Heyd, X. Zhou, T. Ioka, Toshiyoshi Fujiwara, O. Testori, Y.S. Park, A. Allen, Rakesh Kapoor, Bruno Daniele, T. Hirai, Z. Lakkis, I.B. Tan, Y-K Kang, S.A. Aledavood, N. Reynoso, F. Serejo, Sergio Ricci, Jennifer Gansert, M. Miyagi, S. Santi, A. Parthan, A C Wotherspoon, L. Chaigneau, Sumera Rizvi, M.G. Fabrini, Véronique Vendrely, W. Su, V. Shalenkov, L. Tu, G. Numico, Joon Seong Park, J.H. Kim, Hope E. Uronis, Mustafa Benekli, I. Aoyama, M. Gauthier, S. Lazzarelli, W. Liguigli, N. Atsushi, H. Kastrissios, J. Thaler, Z. Zou, T. Tsujinaka, S. Barbero, F. Fiteni, Irene Kührer, Aldo Scarpa, C. Desauw, J.F. Seitz, Takahiro Horimatsu, R. von Roemeling, T. Yamamoto, H.R. Alexander, Timothy Iveson, F.M. Negri, Ermek Tangsakar, Pascal Artru, Jia Zhang, S. Lee, Satoshi Morita, E. Garralda, M. Moore, J. Lee, M. Seilanian Tousi, J. Gornet, Yasuhiro Kodera, Werner Scheithauer, L. Marthey, D. Atanackovic, P. Zhao, D. Wang, I. Davidenko, T.S. Waddell, S. Takeda, N. Fan, R. Kawabata, M. Raponi, Giampaolo Tortora, M. Ogasawara, B. Gruenberger, Guido Gerken, Ivan Borbath, N. Fuse, Denis Smith, Emmanuel Mitry, Vikki Tang, I. Stilidi, Min-Hee Ryu, Tulay Akman, C. Saffery, Roopinder Gillmore, K. Ligier, R. Coriat, T. Namikawa, L. Sun, R. Xu, Gary Middleton, W. Tröger, F. Keil, Bruno Chauffert, K. Achilles, David Cunningham, H. Raies, M.Y. Teo, Y. Hamai, S. Tjulandin, I. Boukovinas, J. Kazakin, J. Beebe-Dimmer, Pippa Corrie, J.A. Ortega, A. Cueff, C. Costa, V. Da Prat, Y. Tanaka, F. Rivera, K. Hashimoto, Tianshu Liu, K. Kato, J.C. Plaza, G. Fountzilas, N. Chaiet, Byung Sik Kim, K. Ueda, Pierre Laurent-Puig, Y.-C. Cheng, Mendel Jansen, T. Salman, C. Papandreou, T. Carothers, H. Van Vlierberghe, M. Rios, S. Barni, Y. Arai, G. Afc, Julia Klech, Bryan C. Fuchs, S.T. Fan, A. Falcone, J-B. Bachet, Y. Fujiwara, S. Navruzov, Fumihiko Kanai, H. Shiah, J. Xia, N. Xu, X. Garcia del Muro, M. Lucchesi, Jae Yong Cho, A. Leon, W. Jin, C. Eng, A.U. Yilmaz, L.-T. Chen, Laurent Bedenne, I. Vynnychenko, Brian Schwartz, J. Ruíz Vozmediano, Toshihiro Tanaka, Jinwan Wang, F. Musante, C. Belli, K. Imanaka, W. Fang, J.P. Fusco, S. Gupta, Daniel H. Palmer, M. Ninomiya, N. Ryuge, M. Djuraev, B. Benzidane, H. Yasui, P.G. Betta, M. Sanon, J. Mizusawa, M. Hou, H. Pan, Y. Osaki, Darren Sigal, E. Schott, J. Rodriguez, E. Wöll, S. Nakamori, Anthony F. Shields, Yasuo Ohashi, M. Raikou, M.W. Bennett, Zhilong Zhao, G. Colucci, R. Stauber, M. Nakamura, T. Nguyen, Xin Li, C. Greco, K. Hanazaki, C. Mao, Y. Matsumura, S. Emoto, Maristella Bianconi, Yoon Ho Ko, E. Trusilova, J. Coombs, H. Iwase, V.A. Gorbunova, M. Lencioni, M. Svrcek, S. Leo, Mahmoud Ellithy, N. Silvestris, Y.H. Min, N. Urata, A. Sainato, K. Yoshimura, U. Boggi, D.C. Huang, T. Tsuzuki, S.H. Hong, K. Ikeda, Mohammed Shaker, Olivier Turrini, Arsene-Bienvenu Loembe, Jaffer A. Ajani, G. Pelletier, Stefano Cascinu, F. Bergamo, I.T. Unek, T. Di Palma, H. Li, Maria Lamar, H. Inagaki, M. Ratti, M. Iida, F. Pons Valladares, S. Caponi, A. Sa-Cunha, A. Passardi, J. Wei, S. Azevedo, W. Wang, S. Luelmo, M. Brighenti, A. Mezlini, Y. Zheng, S. Reddy, M. Milella, S. Nered, D. Li, Carsten Bokemeyer, Manabu Muto, C. Krüger, X.J. Sun, T. Ueno, M. Harrison, F. Cognetti, Y. Kida, M. Kobayashi, S. Akamaru, G. Leonard, Y. Inaba, A. Jayaram, Özgür Ekinci, Y. Bai, F. Subtil, Wasaburo Koizumi, M.A. Fridrik, Pierre Michel, R.C. Turkington, D. Galun, N. De Lio, A. Le Cesne, L. Toppo, Thorsten Füreder, R. Poli, V. Moiseyenko, Jean-Louis Jouve, Y. Lu, A. Babaev, N. Okumura, Isamu Okamoto, G.C. Ruiz, I. Oztop, T. Isobe, W. Fischbach, A. Takashima, Alessandro Bittoni, Y-C Chang, K. Yamaguchi, Vincent J. Picozzi, K. Muro, M. Sebagh, Y. Shindo, S. Beghelli, M. Skoblar Vidmar, Alessandra Mandolesi, M. Reni, K. Nishikawa, Marine Gilabert, Y. Maeda, Francesco Massari, E.B. Ruiz, K. Pan, H. Lou, H.S. Won, C. Diaz, J.P. O'Brien, Shuichi Kaneko, C. Gomez-Martin, J. Sgouros, A. Funakoshi, W. Figg, F. Chai, M.S. Pino, X. Pivot, K. Anvari, J. Turnes, M. Reif, F. Lopez-Rios, W. Cheung, David P. Ryan, M. Oka, I. Varthalitis, A. Deptala, Masatoshi Kudo, F. Romeder, J. Qian, J. Hihara, T. Shibata, T. Yamatsuji, B. Gonzalez-Astorga, B. Allani, Y. Tsuji, J. Liu, Thomas Yau, S. Lim, F. Grosso, Y.D. Zheng, R. Passalacqua, J. Chen, I. Sperduti, H. C. Kwon, C. Cappelli, C. Guettier, O. Nematov, Lanjun Zhou, C. Caparello, F. Bonnetain, R. Ferrara, A. Nashimoto, A. Schumann, Richard Martin Bambury, C. Mazzara, T. Aramaki, B. Saracino, M. Takagi, G. Di Lucca, Philip A. Philip, A. Aloui, Philippe Bachellier, N. Hirabayashi, S. Osanto, S. So, N. Fukushima, K.-H. Yeh, Y. Aoki, M. Baretti, Y-L. Gong, Koichiro Yamakado, C.-H. Hsu, R. Buder, D.G. Power, H. Matsumoto, Chiara Costantini, Y. Xu, G. Tomasello, A. Lopez Pousa, D.K. Lee, F. Di Fiore, O. Polat, K. Suzuki, L. Arbea, R. McDermott, S.-H. Kim, E. Toure, O. Bouche, A. Zaanan, T. Hamaguchi, Mary Geitona, M.H. Tan, M. Antonietti, Italo Bearzi, Juan W. Valle, D. Castaing, H. Shoji, Eylem Pınar Eser, Mario Scartozzi, R. Abdul Rahman, Yukinori Kurokawa, F. Pardo, T. Sasatomi, Y. Kimura, Suguru Yamada, K. El Ouagari, F. Mosca, Yuichiro Doki, A.O. Singh, Goro Nakayama, Lara Lipton, H.J. An, B. Kato, Y. Ezoe, M. Salem, Samantha Bersani, B. Paule, O.E. Carranza Rua, Gabriela Kornek, L. Gray, S. Tamura, J.-F. Blanc, and L. Ginocchi more...
- Subjects
medicine.medical_specialty ,Gastrointestinal tumors ,Performance status ,business.industry ,Hematology ,Severe hypoxia ,Neutropenia ,medicine.disease ,Rash ,Gastroenterology ,Discontinuation ,Non colorectal ,Oncology ,Internal medicine ,Toxicity ,medicine ,medicine.symptom ,business - Abstract
Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G + T arm. The primary efficacy endpoint was a comparison of progression-free survival (PFS) between the combination arms and G alone (80% power to detect 50% improvement in PFS with one-sided alpha of 10%). Summary PFS outcome has previously been reported; more detailed PFS as well as the initial overall survival (OS) data are presented. Results 214 pts were treated; 164 (77%) Stage IV and 50 (23%) Stage IIIB. Median age 65 (range 29-86); 126 M/88 F; 40% ECOG 0/60% ECOG 1. Receiving 6 or more cycles: 32% G; 45% G + T240; 55% G + T340. Median PFS was 3.6 mo in G vs 5.5 mo in G + T240 (p = 0.031) and 6.0 mo in G + T340 (p = 0.008). Poorer prognostic factors (older age, poorer performance status, reduced albumin) were associated with larger treatment effect. Median OS was 7.0 mo in G vs 9.0 in G + T240 and 9.5 mo in G + T340. RECIST best response was 12% in G vs 17% in G + T240 and 27% in G + T340. CA19-9 decreases were significantly greater G + T340. A >50% CA19-9 decrease was 52% with G vs 50% with G + T240 and 70% with G + T340. AEs leading to discontinuation were: 16% G, 15% G + T240 and 11% G + T340. Rash (45% in G + T340) and stomatitis (36% in G + T340) were greater in combination, 4 pts Grade 3 rash. Grd 3/4 thrombocytopenia were 11% G, 39% G + T240 and 59% G + T340 and Grd 3/4 neutropenia were 28% G, 56% G + T240 and 59% G + T340. Conclusions The combination of G plus TH-302 improved the efficacy of G. A TH-302 dose of 340 mg2 was identified for future studies. Skin and mucosal toxicity and myelosuppression were the most common TH-302 related AEs with no increase in treatment discontinuation. Disclosure All authors have declared no conflicts of interest. more...
- Published
- 2012
- Full Text
- View/download PDF
47. 128 Schilddrüsenkarzinome. Stadiengerechte Therapie und Ergebnisse
- Author
-
Wolff H, Birgit Schimpfle, and K. Ridwelski
- Abstract
Die Prognose der Schilddrusenkarzinome ist sehr unterschiedlich. Auf der einen Seite steht das undifferenzierte Schilddrusenkarzinom, das einer der bosartigsten malignen Tumoren uberhaupt ist, auf der anderen Seite das papillare Schilddrusenkarzinom als einer der malignen Tumoren mit der besten Prognose. Grundlage der Therapieplanung ist die histologische Klassifikation. Sie bestimmt mit weiteren prognostischen Kriterien, in erster Linie dem Tumorstaging, die Therapiestrategie. more...
- Published
- 1993
- Full Text
- View/download PDF
48. Die maligne entartete Zyste — Chirurgische Therapiekonsequenz
- Author
-
K. Ridwelski, H. Wolff, K. Gellert, T. Benhidjeb, and H. Lippert
- Abstract
Es wurden 11 Pat. mit maligne entarteten Zysten (9 Zystadenokarzinome des Pankreas und jeweils 1 Zystadenokarzinom der Lunge und des Choledochus) operiert. Die Resektionen wurden nach onkologischen Kriterien stets radikal ausgefuhrt. Bei einer postoperativen Mortalitat von 0% betrug die 5-Jahresuberlebensrate 54,5%. Bei der makroskopisch schweren Differentialdiagnose zwischen Pankreaspseudozyste und Zyste sollte die intraoperative Schnellschnitthistologie als Conditio sine qua non gelten. Wegen des malignen Entartungsrisikos der Choledochuszysten bis zu 30% nach Literaturangaben sind drainierende Operationsmethoden obsolet. Eine Choledochuszyste mus reseziert werden. more...
- Published
- 1992
- Full Text
- View/download PDF
49. [Electrocardiography in pediatrics. 1: Critical considerations of methods and experimental findings]
- Author
-
H, Schwartze, T, Eifrig, K, Ridwelski, and E, Maneck
- Subjects
Asphyxia Neonatorum ,Electrocardiography ,Animals, Newborn ,Heart Conduction System ,Child, Preschool ,Infant, Newborn ,Animals ,Humans ,Infant ,Arrhythmias, Cardiac ,Rats, Wistar ,Child ,Rats - Abstract
The results of experimental cardiology are reported on the basis of the electrophysiology of the heart. The QRS complex of the ECG, representing the spread of excitation through the ventricles, is used as an example to reflect the physiological and pathological events of the heart. The limitations of this example arise from the uncorrected recordings of the potential differences from the body surface. The need to use corrected lead systems is pointed out. The most commonly used FRANK lead system is extremely sensitive to the inaccurate positioning of lead points on the thorax. Evidence for this drawback is given by experimental findings in infantile and juvenile rats. It is clear that inaccurate positioning of electrodes is especially crucial in small subjects. A fundamental criticism of the FRANK lead system used in growing subjects is the impossibility of eliminating the errors caused by the changing geometry of the thorax of children of different ages. Improvement of the physical correction of ECG recordings in children for the purpose of reliable diagnostics is vital. more...
- Published
- 1992
50. [Experiences with surgical therapy of Budd-Chiari syndrome]
- Author
-
J C, Rückert, H, Wolff, K, Ridwelski, B, Rudolph, G, Staffa, and P, Romaniuk
- Subjects
Adult ,Diagnosis, Differential ,Male ,Survival Rate ,Postoperative Complications ,Adolescent ,Liver ,Humans ,Portasystemic Shunt, Surgical ,Female ,Phlebography ,Budd-Chiari Syndrome ,Liver Transplantation - Abstract
The obstruction of the hepatic venous outflow tract with or without involvement of the inferior vena cava results in the Budd-Chiari syndrome (BCS). With its very heterogenous etiology and variable epidemiology the rare disease either takes a chronic or an acute foudroyant clinical course. In general the prognosis is poor. Together with the clinical signs the diagnosis is based on radiological measures and the histology of the hepatic parenchyma. The exact etiological investigation of the BCS is of great significance. Typical findings are discussed and a diagnostic scheme is developed. Between 1979 and 1991, altogether 16 operations were carried out in 13 patients with a BCS. Predominantly there were undertaken a porto-systemic shunt procedure or an orthotopic liver transplantation, respectively, in 6 cases each. The need for an always individually tailored therapeutic strategy of the BCS is underlined by a case history. An overview analyzes the different therapeutic modalities of the BCS and their differential indications. more...
- Published
- 1992
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.